Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882) evalu...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 40; no. 7; p. 762
Main Authors:	O'Malley, David M, Neffa, Maryna, Monk, Bradley J, Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M, Bagameri, Andrea, Wang, Edward W, Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona
Format:	Journal Article
Language:	English
Published:	United States 01.03.2022
Subjects:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use CTLA-4 Antigen - antagonists & inhibitors Female Follow-Up Studies Humans Immune Checkpoint Inhibitors - therapeutic use Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - pathology Prognosis Programmed Cell Death 1 Receptor - antagonists & inhibitors Survival Rate Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - immunology Uterine Cervical Neoplasms - pathology Young Adult
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!